Diagnosis and management of resistant hypertension

医学 螺内酯 依普利酮 盐皮质激素受体 血压 多沙唑嗪 醛固酮 阿替洛尔 内科学 利尿剂 药理学 血管紧张素受体 缬沙坦 血管紧张素转换酶抑制剂 内分泌学 血管紧张素转换酶 血管紧张素II
作者
Miguel Camafort,Reinhold Kreutz,Myeong‐Chan Cho
出处
期刊:Heart [BMJ]
卷期号:: heartjnl-321730 被引量:1
标识
DOI:10.1136/heartjnl-2022-321730
摘要

Resistant hypertension is a condition where blood pressure levels remain elevated above target despite changes in lifestyle and concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (ACE inhibitor or angiotensin receptor blocker) and a diuretic. To be diagnosed as resistant hypertension, maintaining adherence to therapy is required along with confirmation of blood pressure levels above target by out-of-office blood pressure measurements and exclusion of secondary causes of hypertension. The key management points of this condition include lifestyle changes such as reduced sodium and alcohol intake, regular physical activity, weight loss and discontinuation of substances that can interfere with blood pressure control. It is also recommended that current treatment be rationalised, including single pill combination treatment where antihypertensive drugs should be provided at the maximum tolerated dose. It is further recommended that current drugs be replaced with a more appropriate and less difficult treatment regimen based on the patient’s age, ethnicity, comorbidities and risk of drug–drug interactions. The fourth line of treatment for patients with resistant hypertension should include mineralocorticoid receptor antagonists such as spironolactone, as demonstrated in the PATHWAY-2 trial and meta-analyses. Alternatives to spironolactone include amiloride, doxazosin, eplerenone, clonidine and beta-blockers, as well as any other antihypertensive drugs not already in use. New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
手机打卡开不开完成签到,获得积分10
刚刚
fyt完成签到,获得积分20
刚刚
mly完成签到,获得积分10
刚刚
zwenng发布了新的文献求助10
1秒前
1秒前
小杜完成签到 ,获得积分10
2秒前
3秒前
qinglingdao发布了新的文献求助10
4秒前
汪汪汪完成签到 ,获得积分10
4秒前
Alina完成签到 ,获得积分0
4秒前
lhr完成签到 ,获得积分10
5秒前
5秒前
5秒前
6秒前
简单的张哈哈完成签到,获得积分10
6秒前
7秒前
7秒前
7秒前
8秒前
多来米发布了新的文献求助10
8秒前
10秒前
开放菀发布了新的文献求助10
10秒前
11秒前
李泡泡发布了新的文献求助10
12秒前
songjw发布了新的文献求助10
12秒前
长情正豪完成签到,获得积分10
13秒前
13秒前
yuki发布了新的文献求助10
13秒前
malistm发布了新的文献求助10
13秒前
14秒前
14秒前
15秒前
王灿灿应助科研通管家采纳,获得50
15秒前
元谷雪应助科研通管家采纳,获得10
15秒前
李爱国应助科研通管家采纳,获得10
15秒前
科目三应助科研通管家采纳,获得10
15秒前
15秒前
我是老大应助科研通管家采纳,获得10
15秒前
汉堡包应助科研通管家采纳,获得10
16秒前
柚仝发布了新的文献求助10
16秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
XAFS for Everyone 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3143821
求助须知:如何正确求助?哪些是违规求助? 2795450
关于积分的说明 7815080
捐赠科研通 2451485
什么是DOI,文献DOI怎么找? 1304498
科研通“疑难数据库(出版商)”最低求助积分说明 627251
版权声明 601419